Back to "Visceral fat reduced by 9.5% in the CR g..."
Strong Support
causal
Analysis v3
History

In adults with obesity and prediabetes, 14 weeks of eating fewer calories reduces belly fat by 9.5%, which is more than the 4.8% reduction seen with daily 1.8 mg of liraglutide.

82
Pro
0
Against

Mechanism

Synthesis from 1 study

How it works

Eating fewer calories forces the body to burn belly fat and stop making new fat in the liver. A drug that reduces hunger doesn't trigger the same fat-burning and fat-stopping effects, so belly fat decreases less.

Most probable mechanism

In Simple Terms

When a person eats fewer calories, the body breaks down fat stored in the belly area more aggressively and makes less new fat in the liver, causing more belly fat to disappear. A drug that makes a person feel full reduces hunger but does not trigger the same level of fat breakdown or stop liver fat production as effectively.

Causal chain
1

Reduced energy intake lowers insulin secretion and increases glucagon signaling, activating hormone-sensitive lipase in visceral adipocytes

Verified by multiple studies
which leads to
2

Increased lipolysis in visceral adipose tissue releases free fatty acids into circulation for oxidation

Verified by multiple studies
which leads to
3

Reduced hepatic glucose flux and insulin signaling suppress de novo lipogenesis in the liver

Verified by multiple studies
which leads to
4

GLP-1 receptor activation increases satiety but does not significantly suppress hepatic lipid synthesis or enhance visceral adipose tissue lipolysis beyond baseline levels

Verified by multiple studies

Evidence from Studies

Supporting (1)

82

Community contributions welcome

82

Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes

Randomized Controlled Trial
Human
2023 Aug

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Sign up to see full verdict

Source Study

Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes

Score: 82
DOI: 10.1111/dom.15113

Similar Assertions

In adults with obesity and prediabetes, a 14-week diet creating a 390 kcal daily deficit leads to more weight loss and a greater improvement in body fat-to-muscle ratio than daily 1.8 mg liraglutide.

82
0
87%

In adults with obesity and prediabetes, losing weight through calorie reduction maintains muscle mass, but taking 1.8 mg of liraglutide daily causes muscle mass to decrease.

82
0
80%

Adults with obesity who took a drug called liraglutide for 6 months, while eating less and exercising, lost more deep belly fat than those who didn’t — and the study says this medicine might help burn that stubborn fat better.

62
0
76%

In adults with obesity and prediabetes, taking 1.8 mg of liraglutide daily increases feelings of fullness and reduces self-reported desire to eat later, but does not lower the actual amount of calories consumed compared to dieting alone.

0
82
73%

For middle-aged people with extra weight, cutting carbs a lot might burn more belly fat — especially the dangerous kind around organs — even if you lose the same total weight as someone on a low-fat diet.

46
0
72%